Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma (NCT07555938)
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
๐ฉบ Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center โ Duarte, California
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (40 Sites)
Showing the first 25 of 40 sites.
- City of Hope National Medical Center โ Duarte, California
- City of Hope - Lennar Foundation Cancer Center โ Irvine, California
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute โ Washington D.C., District of Columbia
- Emory University Hospital Midtown โ Atlanta, Georgia
- Novant Health Cancer Institute โ Charlotte, North Carolina
- Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists โ Winston-Salem, North Carolina
- TriHealth Cancer and Blood Institute โ Cincinnati, Ohio
- Hamilton Health Sciences - Juravinski Cancer Centre โ Hamilton, Ontario
- HELIOS Klinikum Bad Saarow โ Bad Saarow,
- Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin โ Berlin,
- UKSH, Campus Kiel โ Kiel,
- Evangelismos General Hospital of Athens โ Athens,
- Alexandras General Hospital of Athens โ Athens,
- Anticancer Hospital of Thessaloniki " Theagenio" โ Thessaloniki,
- Rambam Health Care Campus โ Haifa,
- Chaim Sheba Medical Center โ Ramat Gan,
- IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori" โ Meldola, Emilia-Romagna
- Asst Papa Giovanni Xxiii โ Bergamo, Lombardy
- Istituto Clinico Humanitas โ Rozzano, Lombardy
- Toyohashi Municipal Hospital โ Toyohashi, Aichi-ken
- Nagoya City University Hospital โ Aichi,
- Gunma University Hospital โ Gunma,
- Hyogo Medical University Hospital โ Hyลgo,
- University Hospital Kyoto Prefectural University of Medicine โ Kyoto,
- National Hospital Organization Okayama Medical Center โ Okayama,
๐ Contact the Study Coordinator
Phone: (888) 662-6728
Email: global-roche-genentech-trials@gene.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM โ Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma โ Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant โ Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb โ Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma โ Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma โ Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.